TARRYTOWN, N.Y., Oct. 29, 2020 /PRNewswire/ — 

Regeneron has been constantly ranked #1 or 2 High Employer for previous 10 years

Regeneron Prescribed drugs, Inc. (NASDAQ: REGN) today announced that the company was once again ranked as the top company to work for by Science magazine in its annual Top Employers Survey of the global biotech and pharmaceutical industry. Regeneron has placed either first or second for the past ten years, making it the most highly ranked company of the decade. This year, Regeneron placed first based on more than 7,650 responses from people across the industry and stood out with particularly high marks on measures of innovation, being socially responsible and loyal employees.

“We are honored that out of a universe of hundreds of biotechnology and pharmaceutical companies, Regeneron has been ranked #1 by Science for seven of the last 10 years,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer. “The mindset of ‘doing well by doing good’ is woven into everything we do including our relentless drive to bring new medicines to patients in need and our commitment to setting the standard for corporate responsibility.”

“Our science-driven culture has never been more visible than in 2020 as the Regeneron team moved with precision and speed to respond to the COVID-19 pandemic,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer. “Our rapid progress in responding to this emerging disease is the direct result of more than 30 years of science and technology innovation by the remarkable people of Regeneron. Their efforts have already improved the lives of patients with serious eye diseases, cancer, asthma, atopic dermatitis, Ebola and heart disease – and I am confident their greatest innovations lie ahead.”

The Science and Science Careers’ 2020 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries to determine the 20 companies with the best reputations as employers. Respondents to the web-based survey were asked to rate companies based on 21 characteristics. Survey respondents came from North America (67%), Europe (19%), Asia/Pacific Rim (10%) and other regions (4%). The rankings are available in the print issue of Science and at http://www.sciencecareers.org/TopEmployers.  

About Regeneron
Regeneron (NASDAQ: REGN) is a number one biotechnology firm that invents life-transforming medicines for folks with severe illnesses. Based and led for over 30 years by physician-scientists, our distinctive capacity to repeatedly and constantly translate science into medication has led to eight FDA-approved therapies and quite a few product candidates in growth, all of which had been homegrown in our laboratories. Our medicines and pipeline are designed to assist sufferers with eye illnesses, allergic and inflammatory illnesses, most cancers, cardiovascular and metabolic illnesses, ache, infectious illnesses and uncommon illnesses.

Regeneron believes that working as a very good company citizen is essential to delivering on our mission. We method company duty with three objectives in thoughts: to enhance the lives of individuals with severe illnesses, to foster a tradition of integrity and excellence and to construct sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 record of essentially the most “community-minded” corporations in the US. All year long, Regeneron empowers and helps workers to present again by means of our volunteering, professional bono and matching reward packages. Our most vital philanthropic commitments are within the space of science training, together with the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).

For added details about the corporate, please go to www.regeneron.com or comply with @Regeneron on Twitter.

Regeneron Media Relations
Ella Campbell
Tel: +1 (914) 847-7017
[email protected]

SOURCE Regeneron Prescribed drugs, Inc.

Source link


Write A Comment